Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Core Viewpoint - Aethlon Medical, Inc. is advancing its Hemopurifier technology aimed at treating cancer and life-threatening infectious diseases, with recent clinical trial approvals and financial updates indicating progress in its operations and research initiatives [1][5]. Company Updates - Aethlon Medical is focused on the clinical development of its Hemopurifier, which is designed to remove harmful exosomes and viruses from blood, with applications in oncology and organ transplantation [2]. - The company received full ethics approval for a clinical trial of the Hemopurifier in cancer patients, valid until June 13, 2027, to be conducted in Australia [3]. - The Hemopurifier aims to improve response rates to anti-PD-1 therapies, as only about 30% of patients respond to treatments like pembrolizumab or nivolumab [4]. Financial Results - As of March 31, 2024, Aethlon Medical reported a cash balance of approximately $5.4 million, which increased to about $9.1 million by June 25, 2024 [8]. - Consolidated operating expenses for the fiscal year ended March 31, 2024, were approximately $12.6 million, a slight increase from $12.5 million in the previous year, primarily due to payroll increases [8][9]. - The net loss for the fiscal year ended March 31, 2024, was $12.2 million, compared to $12.0 million for the previous fiscal year [11]. Clinical Trials and Research - The company is progressing towards oncology trials in Australia and India, with expectations to enroll the first patient by the end of 2024 [5]. - Aethlon is also conducting a COVID-19 trial in India, with one patient treated so far, while monitoring a new COVID-19 subvariant [6]. - The Hemopurifier has shown potential in capturing previous strains of the H5N1 virus, although it has not been tested against the current strain [7].